- Home
- MPW vs RYTM Comparison
MPW vs RYTM Comparison
Compare MPW & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- RYTM
- Stock Information
- Founded
- MPW 2003
- RYTM 2008
- Country
- MPW United States
- RYTM United States
- Employees
- MPW N/A
- RYTM N/A
- Industry
- MPW Real Estate Investment Trusts
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- RYTM Health Care
- Exchange
- MPW Nasdaq
- RYTM Nasdaq
- Market Cap
- MPW 3.3B
- RYTM 3.8B
- IPO Year
- MPW 2005
- RYTM 2017
- Fundamental
- Price
- MPW $5.24
- RYTM $57.38
- Analyst Decision
- MPW Hold
- RYTM Strong Buy
- Analyst Count
- MPW 6
- RYTM 12
- Target Price
- MPW $5.75
- RYTM $75.42
- AVG Volume (30 Days)
- MPW 8.8M
- RYTM 671.0K
- Earning Date
- MPW 05-01-2025
- RYTM 05-07-2025
- Dividend Yield
- MPW 6.09%
- RYTM N/A
- EPS Growth
- MPW N/A
- RYTM N/A
- EPS
- MPW N/A
- RYTM N/A
- Revenue
- MPW $994,615,000.00
- RYTM $136,863,000.00
- Revenue This Year
- MPW N/A
- RYTM $43.84
- Revenue Next Year
- MPW $5.07
- RYTM $65.62
- P/E Ratio
- MPW N/A
- RYTM N/A
- Revenue Growth
- MPW 23.51
- RYTM 48.88
- 52 Week Low
- MPW $3.51
- RYTM $35.17
- 52 Week High
- MPW $6.55
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- MPW 46.18
- RYTM 43.00
- Support Level
- MPW $5.00
- RYTM $62.69
- Resistance Level
- MPW $5.85
- RYTM $65.53
- Average True Range (ATR)
- MPW 0.20
- RYTM 3.04
- MACD
- MPW -0.01
- RYTM -0.73
- Stochastic Oscillator
- MPW 28.24
- RYTM 1.14
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.